Platelet Activation by a Collagen Analogue in Hemorrhagic Situations

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04483245

Acronym

CAPTURE

Enrollment

Registered

2020-07-23

Start date

2021-12-07

Completion date

2023-04-11

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Collagen Analog, Hemorrhage, Platelet Activation

Brief summary

Dijon University Hospital and the Dijon-based NVH Medicinal Company have developed a recombinant mini-collagen NVH020B with platelet and Willebrand factor binding activity. Its small size and granular, non-fibrillar presentation make it suitable for use as an injectable hemostat in patients with a hemorrhage or other emergency under antiplatelet therapy.

Interventions

BIOLOGICALBlood sampling

Blood sampling

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* \- person who has given their non-opposition to inclusion * adult * Healthy volunteers or controls (patients seen in consultation, without history of hemmorhage, etc.). or * patients with acute bleeding: polytraumatized, or hemorrhage or intracerebral haemorrhage, or bleeding complications at the end surgery (in particular cardiac surgery with ECMO) or * patients with antiplatelet therapy or * patients with thrombocytopenia/thrombopathy

Exclusion criteria

* protected adults (curatorship, guardianship) * person deprived of their liberty by judicial or administrative decision * pregnant, parturient or breastfeeding woman * person unable to express their non-opposition * platelet transfusion on initial management

Design outcomes

Primary

Measure	Time frame	Description
The expression of P-selectin and activated GPIIb/IIIa (PAC1) at the surface of platelets in flow cytometry in response to NVH020B.	Through study completion, an average of 1 year	These 2 markers are absent on the surface of resting platelets. The expression of these 2 markers will make it possible to evaluate the role of the mini-collagen as an activator.

Secondary

Measure	Time frame
Platelet aggregation rate in response to NVH020B	Through study completion, an average of 1 year

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026